US 12,227,579 B2
Bispecific antibody targeting IL-1R1 and NLPR3
Victoria McGilligan, Coleraine (GB)
Assigned to UNIVERSITY OF ULSTER, Coleraine (GB)
Appl. No. 17/275,995
Filed by University of Ulster, Coleraine (GB)
PCT Filed Sep. 16, 2019, PCT No. PCT/EP2019/074744
§ 371(c)(1), (2) Date Mar. 12, 2021,
PCT Pub. No. WO2020/053446, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. 1815045 (GB), filed on Sep. 14, 2018.
Prior Publication US 2022/0041739 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 27/06 (2006.01); A61P 29/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 27/06 (2018.01); A61P 29/00 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/77 (2013.01)] 12 Claims
 
1. A method for the treatment and/or prophylaxis of an inflammatory eye disease, the method comprising:
providing a therapeutically effective amount of an NLRP3 inflammasome modulator which is capable of binding to both of IL-1R1 and NLRP3 and which suppresses activation and/or signaling of the NLRP3 inflammasome;
administering the therapeutically effective amount of said modulator to a subject in need of such treatment,
wherein the NLRP3 inflammasome modulator comprises a bispecific antibody having a first antibody moiety and a second antibody moiety,
the first antibody moiety comprising three heavy chain complementary determining regions (CDRs) and three light chain CDRs, wherein the heavy chain CDRs of the first antibody moiety comprise GYPFTTAG (SEQ ID NO: 60), MNTQSEVP (SEQ ID NO: 61), and AKSVYFNWRYFDV (SEQ ID NO: 62), wherein the light chain CDRs of the first antibody moiety comprise: QSISDY (SEQ ID NO: 63), YAS, and QHGHSFPLT (SEQ ID NO: 64); and
the second antibody moiety comprising three heavy chain complementary determining regions (CDRs) and three light chain CDRs, wherein the heavy chain CDRs of the second antibody moiety comprise GFTFSDYY (SEQ ID NO: 65), ISDGGTYT (SEQ ID NO: 66), and ARGWVSTMVKLLSSFPY (SEQ ID NO: 67), wherein the light chain CDRs of the second antibody moiety comprise TGAVTTSNY (SEQ ID NO: 68), GTN, and ALWYSNYWV (SEQ ID NO: 69).